Your session is about to expire
← Back to Search
1 for Prostate Cancer (DProstate Trial)
Phase 2
Waitlist Available
Led By Theo van der Kwast, MD, PhD, FRCPC
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial gives men different doses of vitamin D3 who are scheduled for prostate removal due to cancer. Vitamin D3 might help by turning into a form that slows down cancer cell growth in the prostate. Vitamin D3, through its active form 1,25-dihydroxyvitamin D3, has been shown to inhibit prostate cancer cell growth and promote differentiation.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Active Control
Group I: 1Active Control1 Intervention
vitamin D3 (400 IU/d)
Group II: 2Active Control1 Intervention
vitamin D3 (10,000 IU/d)
Group III: 3Active Control1 Intervention
vitamin D3 (40,000 IU/d)
Find a Location
Who is running the clinical trial?
Canadian Cancer Society (CCS)OTHER
81 Previous Clinical Trials
41,325 Total Patients Enrolled
7 Trials studying Prostate Cancer
7,535 Patients Enrolled for Prostate Cancer
Mount Sinai Hospital, CanadaOTHER
203 Previous Clinical Trials
69,346 Total Patients Enrolled
Sunnybrook Health Sciences CentreOTHER
674 Previous Clinical Trials
1,565,765 Total Patients Enrolled
31 Trials studying Prostate Cancer
11,991 Patients Enrolled for Prostate Cancer
Share this study with friends
Copy Link
Messenger